{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:33:43Z","timestamp":1755221623047,"version":"3.43.0"},"reference-count":56,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPR"],"DOI":"10.2147\/jpr.s519421","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T04:20:16Z","timestamp":1754713216000},"page":"3987-4001","source":"Crossref","is-referenced-by-count":0,"title":["Postmarketing Research for Opioid Abuse-Deterrent Formulations: A Narrative Review"],"prefix":"10.2147","volume":"Volume 18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-9424","authenticated-orcid":true,"given":"Lynn","family":"Webster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Gudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jody","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Argoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jpain.2018.07.006","volume":"20","author":"Pitcher","year":"2019","journal-title":"J Pain"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.15585\/mmwr.mm7215a1","volume":"72","author":"Rikard","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40122-022-00470-1","volume":"12","author":"Stark","year":"2023","journal-title":"Pain Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"ref6","volume-title":"Implementation of Psychotherapies and Mindfulness-Based Stress Reduction for Chronic Pain and Chronic Mental Health Conditions: A Systematic Review","year":"2021"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e51475","DOI":"10.7759\/cureus.51475","volume":"16","author":"Altawili","year":"2024","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/00325481.2019.1677383","volume":"132","author":"Brennan","year":"2020","journal-title":"Postgrad Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/10738584211030493","volume":"28","author":"Malafoglia","year":"2022","journal-title":"Neuroscientist"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1213\/ANE.0000000000002496","volume":"125","author":"Webster","year":"2017","journal-title":"Anesth Analg"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2147\/JPR.S160255","volume":"11","author":"Meske","year":"2018","journal-title":"J Pain Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"721357","DOI":"10.3389\/fpain.2021.721357","volume":"2","author":"Nadeau","year":"2021","journal-title":"Front Pain Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40122-017-0068-3","volume":"6","author":"Pergolizzi","year":"2017","journal-title":"Pain Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"919773","DOI":"10.3389\/fnmol.2022.919773","volume":"15","author":"Reeves","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/JMDH.S166915","volume":"11","author":"Adler","year":"2018","journal-title":"J Multidiscip Healthc"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.2147\/JPR.S316637","volume":"14","author":"Williamson","year":"2021","journal-title":"J Pain Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/ajgsup.2014.3","volume":"2","author":"Argoff","year":"2014","journal-title":"Am J Gastroenterol Suppl"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/j.pain.0000000000000775","volume":"158","author":"Fillingim","year":"2017","journal-title":"Pain"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.36076\/ppj.2017.110","volume":"20","author":"Manchikanti","year":"2017","journal-title":"Pain Physician"},{"key":"ref20","unstructured":"US GAO. Opioid crisis: status of public health emergency authorities. Available from: https:\/\/www.gao.gov\/products\/gao-18-685r. Accessed October 14, 2024."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.5210\/ojphi.v11i2.10113","volume":"11","author":"Bot\u00e9","year":"2019","journal-title":"Online J Public Health Inform"},{"key":"ref22","unstructured":"Center for Drug Evaluation and Research (CDER). Abuse-Deterrent Opioids--Evaluation and Labeling: Guidance for Industry. Silver Spring, MD: Food and Drug Administration; 2015."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.drugalcdep.2017.01.039","volume":"175","author":"Green","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/ALN.0000000000002031","volume":"128","author":"Litman","year":"2018","journal-title":"Anesthesiology"},{"key":"ref25","unstructured":"National Institute on Drug Abuse. US Overdose Deaths Involving Prescription Opioids. 1999-2022. Available from: https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates. Accessed November 6, 2024."},{"key":"ref26","unstructured":"OXYCONTIN (Oxycodone Hydrochloride) [Prescribing Information]. Stamford, CT, USA: Purdue Pharma LP; 2023."},{"key":"ref27","unstructured":"US Food and Drug Administration. Timeline of selected FDA activities and significant events addressing substance use and overdose prevention. Available from: https:\/\/www.fda.gov\/drugs\/food-and-drug-administration-overdose-prevention-framework\/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose. Accessed April 28, 2024."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/2042098615569726","volume":"6","author":"Simon","year":"2015","journal-title":"Ther Adv Drug Saf"},{"key":"ref29","unstructured":"US Food and Drug Administration. Abuse-deterrent opioid analgesics. FDA. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/abuse-deterrent-opioid-analgesics. Accessed October 2, 2024."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.2147\/JPR.S457982","volume":"17","author":"Webster","year":"2024","journal-title":"J Pain Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40122-016-0062-1","volume":"5","author":"Gudin","year":"2016","journal-title":"Pain Ther"},{"key":"ref32","unstructured":"XTAMPZA ER (Oxycodone) [Prescribing Information]. Stoughton, MA, USA: Collegium Pharmaceutical, Inc.; 2023."},{"key":"ref33","unstructured":"HYSINGLA ER (Hydrocodone Bitartrate) [Prescribing Information]. Stamford, CT, USA: Purdue Pharma LP; 2023."},{"key":"ref34","unstructured":"ROXYBOND (Oxycodone Hydrochloride) [Prescribing Information]. Princeton, NJ, USA: Protega Pharmaceuticals Inc; 2023."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/FTD.0000000000000844","volume":"43","author":"Gadd","year":"2021","journal-title":"Ther Drug Monit"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5055\/jom.0878","volume":"20","author":"Green","year":"2024","journal-title":"J Opioid Manag"},{"key":"ref37","volume-title":"Presented At: PainWEEK","year":"2024"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2147\/JPR.S304805","volume":"14","author":"Green","year":"2021","journal-title":"J Pain Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/CEOR.S340290","volume":"14","author":"Olatoke","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/pmt-2022-0068","volume":"13","author":"Severtson","year":"2023","journal-title":"Pain Manag"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1093\/pm\/pnaa272","volume":"21","author":"Severtson","year":"2020","journal-title":"Pain Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40261-023-01248-9","volume":"43","author":"Jewell","year":"2023","journal-title":"Clin Drug Investig"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/03007995.2023.2178080","volume":"39","author":"Rodriguez","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1097\/j.pain.0000000000000511","volume":"157","author":"Cicero","year":"2016","journal-title":"Pain"},{"key":"ref46","first-page":"21","volume":"13","author":"Petrilla","year":"2020","journal-title":"Am Health Drug Benefits"},{"key":"ref47","unstructured":"Center for Drug Evaluation and Research (CDER). Final Summary minutes of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting. Washington, DC: Food and Drug Administration; 2020."},{"key":"ref48","unstructured":"RMPDS Research. Drug use in the United States. Available from: https:\/\/public.tableau.com\/app\/profile\/rmpds.research\/viz\/PublicDashboard_t2\/Overview. Accessed October 14, 2024."},{"key":"ref49","unstructured":"BioSpace. Protega Pharmaceuticals\u2122 LLC Announces Commercialization of RoxyBond\u2122 (Oxycodone Hydrochloride) Tablets CII in the U.S. Princeton, NJ, USA: BioSpace; 2023."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","volume":"218","author":"Florence","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2016-08-736579","volume":"129","author":"Hunt","year":"2017","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40122-021-00343-z","volume":"11","author":"Dasgupta","year":"2022","journal-title":"Pain Ther"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/AJP.0000000000001034","volume":"38","author":"Beachler","year":"2022","journal-title":"Clin J Pain"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"key":"ref55","unstructured":"Institute for Clinical and Economic Review (ICER). Impact of Abuse Deterrent Formulations of Opioids in Patients with Chronic Pain in the United States: A Cost-Effectiveness Model. Boston, MA: ICER Analytics; 2024."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/pme.12834","volume":"16","author":"Gudin","year":"2015","journal-title":"Pain Med"}],"container-title":["Journal of Pain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/105623","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/105623","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T04:20:21Z","timestamp":1754713221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/postmarketing-research-for-opioid-abuse-deterrent-formulations-a-narra-peer-reviewed-fulltext-article-JPR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":56,"URL":"https:\/\/doi.org\/10.2147\/jpr.s519421","relation":{},"ISSN":["1178-7090"],"issn-type":[{"value":"1178-7090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}